Priority Review for AbbVie's endometriosis therapy

FDA accepted and granted Priority Review to an NDA for elagolix (ABT-620) from AbbVie Inc. (NYSE:ABBV) for the management of endometriosis with associated pain. Its PDUFA date is in 2Q18.

Elagolix is a non-peptide small molecule GnRH antagonist. AbbVie has exclusive, worldwide rights to the product from Neurocrine Biosciences Inc. (NASDAQ:NBIX)...